CClinicalTrials.gg
CompletedNCT05031936Updated Dec 20, 2022

: Intravascular Injection Rates During Cervical Medial Branch Block

An interventional study of cervical spinal injection with 0.2% ropivacaine in Vascular Complications, sponsored by Keimyung University Dongsan Medical Center. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-12-20.

Sponsored by Keimyung University Dongsan Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Study summary

The purpose of this study is to compare using Toughy needle has an advantage of reducing intravascular injection rates during cervical medial branch block.

Read the detailed description

In previous reports, the use of Toughy needle was thought to reduce the incidence of intravascular injection as low as 2.9% during lumbar transforaminal injection.

Blunt needles with a pencil point tip, such as Whitacre needles, are not as sharp at their tip as are Quincke needles, which have bevels. Toughy or blunt needles may therefore be less likely to penetrate a vessel during a procedure. Hence, we postulated the incidence of intravenous uptake would be significantly lower using a Toughy needle than using a Quincke needle for lumbar medial branch block. To confirm the intravascular injection rates, we used the real time fluoroscopy after injection of contrast medium.

The goal of this study was to compare the incidence of intravascular injection rate betweeen Toughy and Quincke needles using real time fluoroscopy during cervical medial branch block

02

Conditions studied

  • Vascular Complications

Keywords

  • intravascular injection
03

In context

Lead sponsor

Keimyung University Dongsan Medical Center is the lead sponsor of 81 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • facet joint arthropathy

Exclusion criteria

Exclusion Criteria:

  • allergy to local anesthetics or contrast medium
  • pregnancy
  • spine deformity
  • neurologic abnormality
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
67 participants (actual)

Study arms

  • Active comparator
    Touhy needle group

    cervical medial branch block using touhy needle

    Procedure: cervical spinal injection with 0.2% ropivacaine

  • Placebo comparator
    Quincke needle group

    cervical medial branch block using quincke needle

    Procedure: cervical spinal injection with 0.2% ropivacaine

Interventions

  • Procedurecervical spinal injection with 0.2% ropivacaine

    spinal injections performed in cervical pillar area to relieve chronic neck pain

06

What researchers measure

Primary outcomes

  1. incidence of intravascular injection

    incidence of intravascular injection during cervical medial branch block

    Time frame: 1 minute after finishing cervical medial branch block

Secondary outcomes

  1. time required to complete cervical medial branch block

    time required to complete cervical medial branch block

    Time frame: Baseline, 1 second after the completion of cervical medial branch block

  2. radiation amout to complete cervical medial branch block

    radiation amout to complete cervical medial branch block

    Time frame: Baseline, 1 second after the completion of cervical medial branch block

07

Study locations

1 site
  • Hong ji HEE
    Daegu, 42601, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05031936
Lead sponsor
Keimyung University Dongsan Medical Center
Responsible party
Ji Hee Hong (Professor, Keimyung University Dongsan Medical Center) — Principal investigator
First posted
Sep 2, 2021
Start date
Aug 12, 2021
Primary completion
Oct 30, 2022
Completion
Oct 30, 2022
Last update
Dec 20, 2022

Study contacts

Ji Hee Hong
principal investigator · Keimyung University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion